IART Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

429.62M

-2.94%

0.800

-17.48%

392.15M

+2.48%

0.488

+19.12%

426.67M

+2.66%

0.552

+22.7%

Estimates Revision

The market is revising Downward the revenue expectations for Integra LifeSciences Holdings Corporation (IART) for FY2025, with the revenue forecasts being adjusted by -2.09% over the past three months. During the same period, the stock price has changed by -4.10%.

Revenue Estimates for FY2025

Revise Downward

-2.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.4%

In Past 3 Month

Stock Price

Go Down

-4.10%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast IART stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

4 Sell

Moderate Sell

Current: 0.000

Low

10.00

Averages

12.33

High

14.00

Current: 0.000

Low

10.00

Averages

12.33

High

14.00

Truist

Hold

downgrade

$15 -> $13

2025-11-03

Reason

Truist

Price Target

$15 -> $13

2025-11-03

downgrade

Hold

Reason

Truist lowered the firm's price target on Integra LifeSciences to $13 from $15 and keeps a Hold rating on the shares. The firm notes it was surprised to see a Q3 revenue miss following multiple rebased outlooks, including last quarter. The intra-quarter issues impacted the business and more than overshadowed progress made on profitability and free cash flow, the analyst tells investors in a research note.

JPMorgan

Robbie Marcus

Underweight

maintain

$12 -> $13

2025-10-31

Reason

JPMorgan

Robbie Marcus

Price Target

$12 -> $13

2025-10-31

maintain

Underweight

Reason

JPMorgan analyst Robbie Marcus raised the firm's price target on Integra LifeSciences to $13 from $12 and keeps an Underweight rating on the shares. The firm updated the company's model.

Citi

Sell

downgrade

$12 -> $11

2025-10-31

Reason

Citi

Price Target

$12 -> $11

2025-10-31

downgrade

Sell

Reason

Citi lowered the firm's price target on Integra LifeSciences to $11 from $12 and keeps a Sell rating on the shares.

Truist

Hold

maintain

$13 -> $15

2025-10-15

Reason

Truist

Price Target

$13 -> $15

2025-10-15

maintain

Hold

Reason

Truist raised the firm's price target on Integra LifeSciences to $15 from $13 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in MedTech. The firm expects "healthy" Q3 revenue and earnings across its coverage but also braces for "stock volatility", with new money feeling notably absent from the space, the analyst tells investors in a research note. Similar to Q2, specialist and fund positioning could be poised to drive excessive reactions on anything counter to crowded positioning, Truist states, adding that it is more inclined to be positive on "cleaner" names where there is less perceived controversy heading into the quarter.

Citizens JMP

Outperform

downgrade

$35 -> $25

2025-05-09

Reason

Citizens JMP

Price Target

$35 -> $25

2025-05-09

downgrade

Outperform

Reason

Citizens JMP lowered the firm's price target on Integra LifeSciences to $25 from $35 and keeps an Outperform rating on the shares. Integra's Q1 sales and earnings results were within guidance ranges, but expectations for Q2 were a bit below, the analyst tells investors in a research note. The firm views Monday's 20% selloff on this news as overdone.

Truist Securities

Richard Newitter

Hold

Maintains

$26 → $19

2025-04-11

Reason

Truist Securities

Richard Newitter

Price Target

$26 → $19

2025-04-11

Maintains

Hold

Reason

Truist lowered the firm's price target on Integra LifeSciences to $19 from $26 and keeps a Hold rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Integra Lifesciences Holdings Corp (IART.O) is 5.04, compared to its 5-year average forward P/E of 14.18. For a more detailed relative valuation and DCF analysis to assess Integra Lifesciences Holdings Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.18

Current PE

5.04

Overvalued PE

19.96

Undervalued PE

8.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.98

Current EV/EBITDA

8.08

Overvalued EV/EBITDA

16.27

Undervalued EV/EBITDA

9.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.24

Current PS

0.56

Overvalued PS

3.38

Undervalued PS

1.10

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IART News & Events

Events Timeline

No data

News

1.0

01-05Globenewswire

Integra LifeSciences CEO to Present at 44th Annual J.P. Morgan Healthcare Conference

9.0

2025-11-12NASDAQ.COM

Integra LifeSciences Obtains FDA Approval for Cardiac Application of CUSA Clarity System

4.0

2025-10-31Benzinga

JP Morgan Keeps Underweight Rating on Integra Lifesciences, Increases Price Target to $13

People Also Watch

Frequently Asked Questions

What is Integra Lifesciences Holdings Corp (IART) stock price today?

The current price of IART is 13.58 USD — it has decreased -2.02 % in the last trading day.

What is Integra Lifesciences Holdings Corp (IART)'s business?

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.

What is the price predicton of IART Stock?

What is Integra Lifesciences Holdings Corp (IART)'s revenue for the last quarter?

Integra Lifesciences Holdings Corp revenue for the last quarter amounts to 402.06M USD, increased 5.57 % YoY.

What is Integra Lifesciences Holdings Corp (IART)'s earnings per share (EPS) for the last quarter?

Integra Lifesciences Holdings Corp. EPS for the last quarter amounts to -0.07 USD, decreased -50.00 % YoY.

What changes have occurred in the market's expectations for Integra Lifesciences Holdings Corp (IART)'s fundamentals?

How many employees does Integra Lifesciences Holdings Corp (IART). have?

Integra Lifesciences Holdings Corp (IART) has 4396 emplpoyees as of January 10 2026.

What is Integra Lifesciences Holdings Corp (IART) market cap?

Today IART has the market capitalization of 1.06B USD.